
EuroSciCon

Clinical Oncology

June 11-13 2018

Dublin, Ireland



Clinical Oncology

www.oncology.euroscicon.com

Day 1, Agenda

General Session

08:00 AM — INTRODUCTION

09:00 AM — PLENARY

10:00 AM — KEYNOTE

Networking & Refreshments Break @ Foyer

	HALL 01	HALL 02	HALL 03
11:00 AM	Talks On: **Clinical Oncology**	Talks On: **Organ Specific Cancer**	Talks On: **Cancer Cell Biology**
	Talks On: **Cancer Biomarkers**	Talks On: **Hemato- Oncology**	Talks On: **Gynecology- Oncology**
	SESSION DISCUSSION	**SESSION DISCUSSION**	**SESSION DISCUSSION**
02:00 PM	Panel Over: **Radiation Oncology**	Panel Over: **Chemotherapy**	Panel Over: **Cancer Biopsy**
	Workshop On: **Radiology**	Workshop On: **Chemotherapy Treatment**	Workshop On: **Surgical Methods**
	Lunch Break @ Restaurant	***Lunch Break @ Restaurant***	***Lunch Break @ Restaurant***
04:00 PM	Talks On: **Oncogenomics**	Talks On: **Chemotherapy treatment**	Talks On: **Surgical Methods**
	Lectures on: **Mutagenesis**	Lectures on: **Cancer Metastasis**	Lectures on: **Biopsied Materials**
06:00 PM	Session On: **Functional analysis of oncogenes**	Session On: **Cancer research for diagnosis**	Session On: **Cancer research for Screening**
	NETWORKING	**NETWORKING**	**NETWORKING**

Day 2, Agenda

General Session

08:00 AM — INTRODUCTION

09:00 AM — PLENARY

10:00 AM — KEYNOTE

Networking & Refreshments Break @ Foyer

	HALL 01	HALL 02	HALL 03
11:00 AM	Talks On: **Skin Cancer**	Talks On: **Recent Developments in Cancer Diagnosis**	Talks On: **Carcinoma**
	Talks On: **Cancer Metastasis**	Talks On: **Pathophysiology**	Talks On: **Breast cancer**
	SESSION DISCUSSION	**SESSION DISCUSSION**	**SESSION DISCUSSION**
02:00 PM	Panel Over: **Precancerous conditions**	Panel Over: **Cancer Screening**	Panel Over: **Functional Analysis of Oncogenes**
	Workshop On: **Multimodal Therapies**	Workshop On: **Screening Methods**	Workshop On: **Genetic Test For Diagnosis**
	Lunch Break @ Restaurant	***Lunch Break @ Restaurant***	***Lunch Break @ Restaurant***
04:00 PM	Talks On: **Cancer Stem Cells**	Talks On: **Cancer Epidemiology**	Talks On: **Database for Cancer Research**
	Lectures on: **Nuclear Imaging**	Lectures on: **Heredity Cancer Syndrome**	Lectures on: **Carcinogenic agent**
06:00 PM	Session On: **Market analysis of cancer diagnostics**	Session On: **Market analysis of cancer diagnostics**	Session On: **Market analysis of cancer diagnostics**
	NETWORKING	**NETWORKING**	**NETWORKING**

Day 3, Agenda

General Session

08:00 AM — INTRODUCTION

09:00 AM — PLENARY

10:00 AM — KEYNOTE

Networking & Refreshments Break @ Foyer

	HALL 01	HALL 02	HALL 03
11:00 AM	Talks On: **Immuno therapy**	Talks On: **Clinical Trials**	Talks On: **Oncology Nursing**
	Talks On: **Harmonal Therapy**	Talks On: **Cancer Drugs and Vaccines**	Talks On: **Nursing Education**
	SESSION DISCUSSION	**SESSION DISCUSSION**	**SESSION DISCUSSION**
02:00 PM	Panel Over: **Cancer Therapy**	Panel Over: **Prophylatic Vaccines**	Panel Over: **Symptom management**
	Workshop On: **Cancer Therapeutic Methods**	Workshop On: **Prophylatic Vaccines**	Workshop On: **Symptom management**
	Lunch Break @ Restaurant	***Lunch Break @ Restaurant***	***Lunch Break @ Restaurant***
04:00 PM	Talks On: **Different Therapies for Cancer Treatment**	Talks On: **Complementary and Alternative Medicines**	Talks On: **Risk Assessment**
	Lectures on: **Cancer: Mode of Existence**	Lectures on: **Drug Development**	Lectures on: **Prevention and Management**
06:00 PM	Session On: **Market Research for Cancer**	Session On: **Market Research for Cancer**	Session On: **Market Research for Cancer**
	NETWORKING	**NETWORKING**	**NETWORKING**

EuroSciCon

2nd Edition of International Conferences on Clinical Oncology and Molecular Diagnostics

JUNE 11-13, 2018 | DUBLIN, IRELAND

AGENDA

Biography

EuroSciCon

Title: The DNA Sequencing Revolution and its' Impact on Clinical Oncology

David I Smith
Mayo Clinic Centre
USA

David I Smith received his Ph.D. in Biochemistry from the University of Wisconsin in Madison in 1978. His first academic position was at Wayne State University School of Medicine and in 1996 he moved to the Mayo Clinic as a Professor in the Department of Laboratory Medicine and Pathology. He is also the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. His laboratory utilizes next generation sequencing to study the different ways that human papillomavirus can cancer in different tissues. His group also studies the common fragile sites which are regions of profound instability found in all individuals.

Title: Desensitization of HLA donor-specific antibodies results in high engraftment rates in patient undergoing allogeneic hematopoietic stem cell transplantation

Douglas E. Gladstone
Johns Hopkins University
USA

Dr. Douglas E. Gladstone is an associate Professor in the Department of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is clinical director of the Outpatient Bone Marrow Transplant Unit. He In 2017, he led an educational program discussing how to lower donor specific antibodies to permissible levels for allogeneic bone marrow transplantation at the annual American Society of Hematology conference.

Title: Proton therapy – the current situation

Karol Sikora
Proton Partners International
UK

Karol Sikora is founder and Chief Medical Officer of Proton Partners International. He was also founder and CMO of Cancer Partners UK, now GenesisCare, which built Britain's largest network of independent cancer treatment centres. He was Professor and Chairman of the Department of Cancer Medicine at Imperial College School of Medicine and is still honorary Consultant Oncologist at Hammersmith Hospital, London. He is Dean of Medicine at Britain's first independent Medical School at the University of Buckingham. He is a Fellow of Corpus Christi College, Cambridge where he obtained a double first and trained at The Middlesex and St Bartholomew's Hospitals, researching with Nobel Prize winner, Dr. Sydney Brenner.

Biography

EuroSciCon

Title: Surgery of brain metastases

Philippe Metellus
Clairval Hospital Centre,
France

Philippe METELLUS is Professor of Neurosurgery at the Clairval Hospital Center in Marseille, France. He is specialized in brain tumors and is the actual leader of the Glioma and the Brain Metastases program in France. Besides his clinical activity, he is running translational and basic science research program in the INSERM UMR 911 unit. His clinical and research activities are focused on Gliomas and Brain Metastases. A surgical research program on gliomas located in eloquent areas including awake craniotomies with electroencephalographic recordings has been developed with his neurological team in 2011. Also, a transfer laboratory at the Aix-Marseille University. These programs involve a multi-disciplinary brain tumor consortium including, Neurologists, Neuro-Oncologists, Medical-Oncologists, Radiation-Oncologists, Neuro-Radiologists, Pathologists and the translational oncology university platform.

Title: Utility Of Molecular Profiling For Diagnosing Patients With Cancer Of Unknown Primary In A Population-Based Cohort.

Julie Smith-Gagen
University of Nevada
USA

Julie Smith-Gagen MPH, PhD is an Associate Professor at the University of Nevada, Reno. As an epidemiologist, her work uses epidemiology to inform health policy to promote equity in utilization and access to healthcare. Her current area of focus is on the real-world use of diagnostics and treatments for patients with Cancer of Unknown Primary. Another area of focus is on prevention treatments that can slow the progression of nonalcoholic steatohepatitis; liver damage causes by fat buildup and inflammation. Dr. Smith Gagen has published in many peer-reviewed high impact journals including but limited to Statistical Methods in Medical Research, Journal of Epidemiology and Community Health, Psycho-Oncology, Journal of Cancer Research and Clinical Oncology, Cancer Causes and Control and Women's Health

Title: Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men

Lital Keinan Boker
University of Haifa

Lital Keinan Boker, MD, PhD, MPH, has her expertise in cancer epidemiology, particularly breast cancer. She is involved in etiological research, as well as early detection and log-term outcomes of cancer survivors. In addition to that, she is also involved in the research of long-term physical health outcomes in Holocaust survivors, and now starts studying also the second generation of Holocaust survivors. Her research work is done within her capacity as both the Deputy Director of the Israel Center for Disease Control in the Israel Ministry of Health, and her position as an Associate Professor in the School of Public Health in the University of Haifa.

Biography

EuroSciCon

Title: Current Treatment Option of CML; focusing on Radotinib: Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 mg BID or Imatinib: RERISE 36 Months Follow-up

Young Rok Do
Keimyung University
School of Medicine,
Korea

Prof. YR. Do has his expertise in evaluation and passion in improving the outcome of CML treatment. His open and contextual evaluation model based on clinical trial creates new pathways for improving CML. He has built this achievement after years of experience in research, evaluation, teaching and administration both in hospital and education institutions

Title: Development of PI3K inhibitor copanlisib – new insights and outlook

Ningshu Liu
Bayer AG, Germany

Ningshu Liu has multiple deciplins her research interests in in evaluation and passion in improving the health and wellbeing. Her open and contextual evaluation model based on responsive constructivists creates new pathways for improving healthcare. She has built this model after years of experience in research, evaluation, teaching and administration both in hospital and education institutions. The foundation is based on fourth generation evaluation (Guba& Lincoln, 1989) which is a methodology that utilizes the previous generations of evaluation: measurement, description and judgment. It allows for value-pluralism. This approach is responsive to all stakeholders and has a different way of focusing.

Title : Using different next generation sequencing technologies to study the role of human papillomavirus integration in the development of cancer

David I Smith
Mayo Clinic Centre
USA

David I Smith received his Ph.D. in Biochemistry from the University of Wisconsin in Madison in 1978. His first academic position was at Wayne State University School of Medicine and in 1996 he moved to the Mayo Clinic as a Professor in the Department of Laboratory Medicine and Pathology. He is also the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. His laboratory utilizes next generation sequencing to study the different ways that human papillomavirus can cancer in different tissues. His group also studies the common fragile sites which are regions of profound instability found in all individuals.

Biography

EuroSciCon

Title: Pre-clinical analysis of the feasibility of tumour infiltrating lymphocyte therapy for paediatric brain tumours

Gray Kueberuwa
University of Manchester, UK

Gray Kueberuwa, is a doctor of oncology working in the Clinical and Experimental Immunology Group within the Department of Cancer Sciences at the University of Manchester, UK. His research interests include chimeric antigen receptor (CAR) T-cell therapy of cancer, tumour infiltrating lymphocyte (TIL) therapy of cancer and the production of immune regulatory agents from within therapeutic cells.

Title: Electrochemotherapy as a new approach on pancreatic cancer and on liver metastases

Francesco Izzo
National Cancer Institute of Naples, Italy

Dr Izzo is Director and Chief of the Hepatobiliary and Pancreatic Unit, within the Department of Surgical Oncology at the National Cancer Institute of Naples. His clinical practice and research focuses on new surgical oncology treatments and he has been a pioneer in designing improved techniques for surgical removal of hepatic tumours and direct tumour injection therapies. Additionally, Dr Izzo is Principal Investigator of a number of national and international protocols in this field and has authored or co-authored more than 220 publications and 18 book chapters relating to the treatment of patients with HPB tumours. Total Impact Factor: 638,003 ; H-INDEX: 35; Sum of the times citated: 7.017; Database utilized: SCOPUS for H-Index and Bibliosan for IF

Title: Current Concepts and Future of Salivary Markers for Diagnosing Oral Squamous Cell Carcinoma: A Review and Meta-Analysis of Relevant Published Studies

Esam Ahmed Z. Omar
Taibah University

Graduated from University of London (Eastman Dental Institute, United Kingdom) after a residency program at UCL Hospitals and Eastman Dental Institute, London, UK, with Master Degree and Fellowship of Royal College of Surgeons in Ireland FFDRCSI in 2005. He is a fellow of International Association of Oral and Maxillofacial Surgery and Senior Fellow of Head and Neck Optical Diagnostic Society, London. UK.

Biography

EuroSciCon

Title: Targeting protein phosphatase methylesterase 1 to induce apoptosis in NSCLC cells through its ubiquitylation and proteasomal degradation

Wei-Lin Yen
Medical Research Centre Cardinal Tien Hospital Taiwan.

Wei-Lin Yen has completed her master's degrees from China Medical University, Taiwan. She has been working in Shin Kong Wu Ho-Su Memorial Hospital from 2013 to 2016, now she works in Medical Research Center, Cardinal Tien Hospital.

Title: Chimerism monitoring of pediatric oncology patients after hematopoietic stem cell transplantation using STR analysis

Ebru Dündar Yenilmez
Cukurova University School of Medicine, Turkey

Dr. Ebru Dündar Yenilmez, PhD-Medical Biochemistry, now is an Assistant Lecturer and Specialist of Medical Biochemistry, General Manager Assistant of the Prenatal Diagnosis Laboratory of the Department. Member of Turkish Biochemistry Society, International Federation of Clinical Chemistry (IFCC), Europan Society of Human Genetic (ESHG). She got her B Sc in Biology, M Sc in Medical Biochemistry, Specialist in Medical Biochemistry, Medicine doctor's degree (Ph.D.) at Medicine Faculty of Cukurova University. Dr. Ebru Dündar Yenilmez researches focus on the molecular basis of the inherited blood disorders (Thalassemias, sickle cell anemias), cystic fibrosis, hemophilia's, congenital adrenal hyperplasia etc., gene expression, donor chimerism monitoring of pediatric hematology/oncology patients.

Title: DNA repair imbalance is associated with tumor aggressiveness and modulates response to chemotherapy in colorectal cancer

Jenifer Saffi
Federal University of Health Sciences of Porto Alegre (UFCSPA) - Brazil

Phamacist, PhD in Biochemistry and Post-Doc at the "Institut de Cancérologie Gustave Roussy" in Villejuif –). Biochemisty Professor at the Federal University of Health Sciences of Porto Alegre (UFCSPA), where she coordinates the Laboratory of Genetic Toxicology. She has more than 100 international papers published in the field of genetic toxicology. Her main research area is DNA repair and mutagenesis in eukaryotic cells, focusing on the involvement of the DNA repair mechanisms France in the cytotoxicity of antitumor drugs and DNA damage response in colorectal cancer.

Biography

EuroSciCon

Title: Solution proposed to a 2000-year-old problem in oncology

Michael Retsky
Harvard TH Chan School of Public Health, USA

Michael Retsky (PhD in Physics from University of Chicago) made a career change to cancer research thirty years ago. He is Research Associate at Harvard TH Chan School of Public Health and Honorary Reader at University College London. He was on Judah Folkman's staff at Harvard Medical School for 12 years. Retsky is Editor of a Springer-Nature book on the breast cancer project published July 2017. After diagnosis of stage IIIc colon cancer in 1994, he was the first person to use what is now called metronomic adjuvant chemotherapy. He is a founder and for 10 years was on the Board of Directors of the Colon Cancer Alliance. He has published more than 70 papers in physics and cancer.

Title: Autologous Stem Cell Transplant in complete remission has better survival in patients with Lymphoma: A Single Centre Experience

Rayaz Ahmed
Rajiv Gandhi Cancer Institute and Research Centre

Dr. Rayaz Ahmed has obtained his DM in Clinical Hematology from CMC Vellore and worked as an Associate Professor in Hemato Oncology Unit of CMC Vellore during a period of 2010-2013. He is currently working as the Consultant in Hemato-Oncology Unit at Rajiv Gandhi Cancer Institute & Research Centre,New Delhi, India. His areas of interest include bone marrow transplant / stem cell transplant, aplastic anemia, thalassemia, sickle cell anemia, MDS, myeloma, lymphoma and acute and chronic leukemias. He has published 24 papers in national and international journals.

Title: Quality Control in a Routine Molecular Diagnostic Laboratory: Scope and Challenges

Rekha Chaubey
Institute of Medical Sciences

Dr Rekha Chaubey has been working as a Young Scientist, Molecular Hematology lab, Department of Hematology, AIIMS, New Delhi, India. Her research interests are cancer biology (Hematology) and molecular diagnostics. She has completed her PhD and post Doctorate from the same department .She has received best thesis award for her PhD work in the field of oncology from AIIMS, New Delhi. She has an experience of twelve years in hematology molecular diagnostics. She is author and coauthor of several book chapters and paper published from the department. She also received several awards in national and international conferences for presenting her work.

Biography

EuroSciCon

Title: Evidence-based practice for the sub-classification of NSCLC using current WHO criteria. Moving from targeted therapy to immunotherapy.

Qing Kay Li
Johns Hopkins University
School of Medicine
USA

Dr. Qing Kay Li is an associate professor of department of pathology at the Johns Hopkins University School of Medicine. She has the American Board of Pathology certification in surgical and cytopathology. Her clinical expertise includes surgical pathology, cytopathology, and oncological pathology. Dr. Li is also a PI at the Johns Hopkins Biomarker Discovery Center. Her research interest is focusing on the application of advanced molecular techniques to the field of cancer biology, particularly in the field of early detection of lung and prostate cancer. Dr. Li serves as editorial board members for several journals; committee members of the American Society of Cytopathology, Papanicolaou Society of Cytopathology, NIH/NCI lung cancer, and kidney cancer working group; study sections of government agents and private organizations

Title: Oral Squamous Cell Carcinoma (OSCC) staging system: what other prognostic factors should be considered

Esam Ahmed Z. Omar
Taibah University

Esam Ahmed Z. Omar is Graduated from University of London (Eastman Dental Institute, United Kingdom) after a residency program at UCL Hospitals and Eastman Dental Institute, London, UK, with Master's Degree and Fellowship of Royal College of Surgeons in Ireland FFDRCSI in 2005. He is a fellow of International Association of Oral and Maxillofacial Surgery and Senior Fellow of Head and Neck Optical Diagnostic Society, London. UK.

Past Affiliates

Melissa Joyner
The University of Texas, USA

William Jia
University of British Columbia, Canada

Chiung-Fang Chang
Far Eastern Memorial Hospital

Adrian Senderowicz
Cerulean Pharma, USA

Qiaofei Liu
Peking Union Medical College Hospital, China

Han-Heom Na
Kangwon National University, South Korea

Vincent Balaya
University Paris Descartes, France

Lidija Covic
Tufts Medical Center, USA

Jaecheong Lim
Korea Atomic Energy Research Institute, South Korea

Xueqing Wang
Beijing Jishuitan Hospital, China

Shahla Masood
UF Health Breast Center, USA

Darya Tsvirkun
The Hebrew University of Jerusalem

Xudong Miao
Zhejiang University, China

Gaiane M. Rauch
University of Texas Cancer Center, USA

Surangkana Sanmai
Khon Kaen University

Michael R Olin
University of Minnesota, USA

Michael Thompson
University of Wroclaw,Canada

Katarina Jeremić
Belgrade University School of Medicine

Raushan Kurmasheva
University of Texas Health Science Center, USA

Emmanuelle Charafe-Jauffret
University of Mediterranée, France

Hazan Ozyurt
Lutfi Kirdar Kartal Education and Research Hospital

Norbert Graf
Saarland University, Germany

Chang Gong
Sun Yat-Sen University, China

Kennedy Gonçalves Pacheco
Vascular Surgeon and Phlebologist

Liqin Du
Texas State University, USA

Ragheed Al-Mufti
The West of London Breast Cancer Network, UK

Tevfik Guvenal
Celal Bayar University School of Medicine

Ravi Radhakrishnan
University of Pennsylvania, USA

Maude Hébert
University of Quebec in Trois-Rivieres, Canada

Vineet Talwar
Rajiv Gandhi Cancer Institute and Research Centre

Past Affiliates

Christian G. Chaussy
University Regensburg,Germany , Germany

Guan Chen
Medical College of Wisconsin, USA

Aleksandar Stefanović
Association of gynecologist and obstetricians of Serbia

KN Leung
Chinese University of Hong Kong, China

M.A. Nezami MD
Pacific Medical Center of Hope, United States

Tommy Nai-Jen Chang
Chang Gung Memorial Hospital

Gregory G. Passmore
Augusta University, United States, USA

Mouad Edderkaou
Cedars-Sinai Medical Center, USA

Hossam El Sokkary
Alexandria university

Jim Burgess
Augusta University United States, United States

Yiu-Lian Fong
Johnson & Johnson Innovation, UK

Somashekhar S.P
Manipal Hospital

Zoya Vinokur
New York City College of Technology, USA

Karl R Aigner
Medias Klinikum GmbH & Co. KG

Kannan Vaidyanathan
Pushpagiri Institute of Medical Science & Research Center

Benedict Benigno
Ovarian Cancer Institute, USA

Alireza Heidari
Professor, USA

Georgios Stamatakos
National Technical University of Athens

Sang Y Lee
Penn State Health Milton S. Hershey Medical Center, USA

MA Nezami
President, USA

Elizabeth Algar
Hudson Institute of Medical Research, Australia

Jan Lewin
University of Texas MD Anderson Cancer Center, USA

Sputova K
University of Miami Miller School of Medicine, USA

Ines Vasconcelos
Berlin Oncological Center Kurfürstendamm, Germany

Hiroshi Osawa
Edogawa Hospital, Japan

Nematallah Mansour
Université de Sherbrooke, Canada

Nalini Kant Pati
Australian National University, Australia

Saad Kenderian
Mayo Clinic,USA

Omer Kucuk
Emory University, USA

Nahla Ali Mobark
King Fahad Medical City

Thomas Mehrling CEO
Mundipharma EDO GmbH, Switzerland

Qun Lu
East Carolina University, USA

Jessy S Deshane
University of Alabama at Birmingham, USA

Past Affiliates

Giuseppe Leone
Catholic University

Taisei Nomura
Osaka University, Japan

Ines Vasconcelos
Berlin Oncological Center Kurfürstendamm, Germany

David J. Bearss CEO
Tolero Pharmaceuticals, USA

Jennifer L Young
The Urology Group, USA

Michael G Hanna
Vaccinogen Inc., USA

Jack Sariego
Aria-Jefferson Health System, USA

Lucia R Languino
Thomas Jefferson University, USA

María del Rosario Dávalos Gamboa
University of San Simón

Ashutosh Kothari
Guys Hospital, UK

Jiao Zhang
East Carolina University, USA

Ines Vasconcelos
Berlin Oncological Center Kurfürstendamm, Germany

Hong Zhang
University of Texas-M D Anderson Cancer Center, USA

Aejaz Sayeed
Thomas Jefferson University, USA

Alex Agyekum
Bikbok Herbal Centre

Yun Gong MD
Anderson Cancer Center, USA

Kristina Shahriari
Drexel University, USA

María Marcela Barrio
Centro de Investigaciones Oncológicas Fundación Cáncer

Sheldon Milstien
Virginia Commonwealth University, USA

Zhi Ping Xu
University of Queensland, Australia

Petrousjka van den Tol
VU University Medical Center

Senqing Chen
Jiangsu Institute of Cancer Research, China

David K. Imagawa
University of California, USA

Marco Bernini
Careggi University Hospital

Julia Gerasimenko
Cardiff University, UK

Rupinder Kaur
Deakin University, Australia

Baek Kwang-In
The institute of Koryo Acupotomology, Korea

Feng Yan
Nanjing Medical university Hospital, China

Veronica J James
Australian National University, Australia

Larysa M.Skivka
Professor, Ukraine

Andreas Lehmann
Fraunhofer Institute for Ceramic Technologies and Systems

Pascal H G Duijf
University of Queensland, Australia

Waleed Seif El-Din Mohamed Mostafa
Professor Cairo University

Past Affiliates

Juan F Roman
Cambridge Consultants Medical Technology, UK

Jagat R Kanwar
Deakin University, Australia

Mohamed EL-Far
Professor, Egypt

Oleg Gerasimenko
Cardiff University, UK

Susan J Done
University of Toronto, Canada

Bogusław Maciejewski
Director, Poland

Julia Gerasimenko
Cardiff University, UK

Igor Buchwalow
University of Muenster, Germany

David Huang
Professor, China

Jessy Deshane
University of Alabama at Birmingham, USA

Thomas Kieber-Emmons
University of Arkansas for Medical Science, USA

Nina Tuncel
Professor, Turkey

Andreas Lehmann
Fraunhofer Institute for Ceramic Technologies and Systems

Stefan B. Eichmüller
German Cancer Research Center, Germany

Bahram Mofid
Shahid Beheshti University of Medical Sciences

Jennifer Wu
Hollings Cancer Centre, USA

Raj Tiwari
New York Medical College, USA

Sheeba Jacob
Mumbai University

Peter Weightman
University of Liverpool, UK

Alex Dommann
Swiss Federal Laboratories for Materials Science and Technology,

Fahri Saatcioglu
Oslo University Hospital

Alok De
Kansas City Vet Center, USA

Niccola Funel
University of Pisa

Elif Damla
Istanbul Kultur University

Jeffrey B Ulmer
Novartis Vaccines & Diagnostics, USA

Wassil Nowicky
Ukrainian Anti-Cancer Institute

Guldeniz Karadeniz Cakmak
Bulent Ecevit University

Michael Goris
Stanford University School of Medicine, USA

Francesco Zinno
University of Rome Tor Vergata

Diptendra K Sarkar
Professor, IPGMER

Shuo Li
GE Healthcare, Canada

Jan Jacques Michiels
Goodheart Institute

Sadir Jumaa Alrawi
Tawam Cancer Centre

Past Affiliates

Leung KN
The Chinese University of Hong Kong, China

Shikai Wu
Academy of Military Medical Sciences, China

Deepak Kaul
Postgraduate Institute of Medical Education & Research, India

Morio Sato
Wakayama Medical University, Japan

Shahram Bahmanyar
Karolinska Institutet Stockholm, Sweden

Fritz Lahrtz
Isenbruck Bösl Hörschler LLP Prinzregentenstr, Germany

IkuoTooyama
Shiga University of Medical Science, Japan

Cohen-Armon
Tel-Aviv University

Yaffa Mizrachi Nebenzahl
Ben Gurion University of the Negev

Doungdean Tummanatsakun
Khon Kaen University

Anne Ryhänen
University of Turku

Mahmoud El-Foudeh
King Faisal Specialist Hospital & Research Center, Saudi Arabia


Kuo-Wang Tsai
Kaohsiung Veterans General Hospital

Hsu-Shan Huang
Taipei Medical University

Giulio Tarro
Foundation de Beaumont Bonelli for Cancer Research, Italy

Shahram Bahmanyar
Karolinska Institutet Stockholm, Sweden

Syed Rahmanuddin
Radiology Center City of Hope, USA



PLAN A TRIP TO DUBLIN: DESTINATION OF CLINICAL ONCOLOGY 2018

Dublin is the capital of the republic of Ireland, located on Ireland's east coast at the mouth of the River Liffey. Dublin has 1.5 million inhabitants. Alpha ranking is given to Dublin by the Globalization and World Cities Research Network (GaWC) as a global city, which secures one among the top thirty cities in the world. It is a historical and existing centre for education, arts, administration, economy and industry. Its historic buildings include Dublin Castle and magnificent St Patrick's Cathedral, founded in 1191. City parks encompass landscaped St Stephen's Green and huge Phoenix Park, containing Dublin Zoo. The National Museum of Ireland explores Irish heritage and culture. In 2018, Dublin Plans to gather prominent educational scientists, researchers and instructors to discuss about the current trends in Clinical Oncology and Molecular Diagnostics.

EXPLORE THIS EMBODIMENT TOURIST HERITAGE

Dublin, a city which comprises both modern architecture and historical monuments is a place worth visiting once in a lifetime. Following are the famous tourist marvels of the city





City Attractions



